Esiflo 500 Trans Capsules 30 Capsules

babies: it is not applicable. lactating mother: it is safe during breastfeeding.
pregnancy: it is unsafe during pregnancy. limited studies have shown harmful effects on the developing baby.
please consult your doctor. driving: it is not applicable.
alcohol: information is not available on whether it is safe to consume alcohol with this medication. kidney: not applicable. liver: not applicable..

Nausea Headache Vomiting Respiratory tract infection Fungal infections in the mouth Sore throat Hoarseness of voice Cough Musculoskeletal pain Increased heart rate.

ESIFLO capsules is an bronchodilator and steroid. it works by relaxing the muscles in the airways and widen the airways.
it works by stopping the release of chemical messenger that causes inflammation of the airways. together they make breathing easier..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• ESIFLO capsules used to treat asthma and chronic obstructive pulmonary disorder • take this medication at the same time each day • take the first dose of this medicine under medical supervision as it may cause wheezing or tightening of the airways after using this medication • a dry mouth may occur as a side effect. to reduce this side effect frequently, wash your mouth, keep good oral, increased water intake, and sugarless candy • take this medication as prescribed by your doctor.

serious • fluticasone propionate + atazanavir: concurrent use leads to an increase in the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism • fluticasone propionate + clarithromycin: concurrent use leads to increase the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism • fluticasone propionate + conivaptan: concurrent use leads to increase the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism • salmeterol xinafoate + fosamprenavir: concurrent use leads to an increase in the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism monitor closely • salmeterol xinafoate + fedratinib: concurrent use leads to increase the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism • salmeterol xinafoate + letermovir: concurrent use leads to an increase in the level or effect of fluticasone intranasal by affecting hepatic/intestinal enzyme cyp3a4 metabolism.